Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ecologic Barrier
- Development stage
- Preclinical
- Lead developer
- Winclove Probiotics
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Ecologic® Barrier is a multi-strain probiotic dietary supplement developed by Winclove Probiotics. It is a specific formulation of nine bacterial strains: *Bifidobacterium bifidum* W23, *Bifidobacterium lactis* W51, *Bifidobacterium lactis* W52, *Lactobacillus acidophilus* W37, *Levilactobacillus brevis* W63, *Lacticaseibacillus casei* W56, *Ligilactobacillus salivarius* W24, *Lactococcus lactis* W19, and *Lactococcus lactis* W58. The product is designed to modulate the gut microbiome to improve intestinal barrier function and reduce systemic low-grade inflammation. By altering the gut microbiota's function, it is hypothesized to decrease circulating lipopolysaccharide (LPS) levels, thereby favorably impacting cardiometabolic health, liver function, and the gut-brain axis. It has been clinically studied for various conditions, including obesity, type 2 diabetes, metformin intolerance, migraine, and mood disorders.
- Brand names
- Ecologic® BarrierOmni-Biotic HetoxTarget gb-X™
- Other names
- multispecies probiotic formulationprobiotic formulation consisting of multiple bacterial strains
Beyond the preview
Go deeper on Ecologic Barrier.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ecologic Barrier.